Loading clinical trials...
Loading clinical trials...
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Conditions
Interventions
GSK3228836
PegIFN
+1 more
Locations
49
United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
Iowa City, Iowa, United States
GSK Investigational Site
Detroit, Michigan, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
Start Date
January 28, 2021
Primary Completion Date
February 17, 2023
Completion Date
February 17, 2023
Last Updated
May 2, 2024
NCT07417553
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions